BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-El-Enein M, Duda GN, Gruskin EA, Grainger DW. Strategies for Derisking Translational Processes for Biomedical Technologies. Trends Biotechnol 2017;35:100-8. [PMID: 27499276 DOI: 10.1016/j.tibtech.2016.07.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Cathomen T, Schüle S, Schüßler-Lenz M, Abou-El-Enein M. The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol 2019;37:120-3. [PMID: 30017092 DOI: 10.1016/j.tibtech.2018.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
2 Fortunato A, Grainger DW, Abou-El-Enein M. Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Adv Drug Deliv Rev 2018;136-137:97-104. [PMID: 29408180 DOI: 10.1016/j.addr.2018.01.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
3 Abou-El-Enein M, Volk HD, Reinke P. Clinical Development of Cell Therapies: Setting the Stage for Academic Success. Clin Pharmacol Ther 2017;101:35-8. [PMID: 27709611 DOI: 10.1002/cpt.523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
4 Qiu T, Wang Y, Liang S, Han R, Toumi M. Partnership agreements for regenerative medicines: a database analysis and implications for future innovation. Regen Med 2021;16:733-55. [PMID: 34431716 DOI: 10.2217/rme-2021-0011] [Reference Citation Analysis]
5 Kurtz A, Elsallab M, Sanzenbacher R, Abou-el-enein M. Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends in Molecular Medicine 2019;25:8-19. [DOI: 10.1016/j.molmed.2018.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Letourneur D, Joyce K, Chauvierre C, Bayon Y, Pandit A. Enabling MedTech Translation in Academia: Redefining Value Proposition with Updated Regulations. Adv Healthc Mater 2021;10:e2001237. [PMID: 32935923 DOI: 10.1002/adhm.202001237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Parrish J, Lim K, Zhang B, Radisic M, Woodfield TBF. New Frontiers for Biofabrication and Bioreactor Design in Microphysiological System Development. Trends Biotechnol 2019;37:1327-43. [PMID: 31202544 DOI: 10.1016/j.tibtech.2019.04.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
8 Gomez-Florit M, Pardo A, Domingues RMA, Graça AL, Babo PS, Reis RL, Gomes ME. Natural-Based Hydrogels for Tissue Engineering Applications. Molecules 2020;25:E5858. [PMID: 33322369 DOI: 10.3390/molecules25245858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Fritsche E, Volk H, Reinke P, Abou-el-enein M. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology 2020;38:1099-112. [DOI: 10.1016/j.tibtech.2019.12.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 26.0] [Reference Citation Analysis]
10 Coentro JQ, De Pieri A, Gaspar D, Tsiapalis D, Zeugolis DI, Bayon Y. Translational Research Symposium-collaborative efforts as driving forces of healthcare innovation. J Mater Sci Mater Med 2019;30:133. [PMID: 31792698 DOI: 10.1007/s10856-019-6339-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Raths S, Parkel S, Bredmose J, Daussin V. Mind the gap! A survey of the challenges of biomarker commercialization. Drug Discovery Today 2020;25:22-6. [DOI: 10.1016/j.drudis.2019.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Caicedo A, Aponte PM, Cabrera F, Hidalgo C, Khoury M. Artificial Mitochondria Transfer: Current Challenges, Advances, and Future Applications. Stem Cells Int 2017;2017:7610414. [PMID: 28751917 DOI: 10.1155/2017/7610414] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
13 Busscher HJ, Alt V, van der Mei HC, Fagette PH, Zimmerli W, Moriarty TF, Parvizi J, Schmidmaier G, Raschke MJ, Gehrke T, Bayston R, Baddour LM, Winterton LC, Darouiche RO, Grainger DW. A Trans-Atlantic Perspective on Stagnation in Clinical Translation of Antimicrobial Strategies for the Control of Biomaterial-Implant-Associated Infection. ACS Biomater Sci Eng 2019;5:402-6. [PMID: 30775431 DOI: 10.1021/acsbiomaterials.8b01071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
14 Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7:676-685. [PMID: 30063299 DOI: 10.1002/sctm.17-0282] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 22.0] [Reference Citation Analysis]
15 Ren Y, Fagette PH, Hall CL, Broers H, Grainger DW, Van Der Mei HC, Busscher HJ. Clinical translation of the assets of biomedical engineering – a retrospective analysis with looks to the future. Expert Review of Medical Devices 2019;16:913-22. [DOI: 10.1080/17434440.2019.1685869] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov 2021;2:408-22. [PMID: 34568831 DOI: 10.1158/2643-3230.bcd-21-0084] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]